Clinical Trial Update: LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating PCSK9 monoclonal antibody with statin therapy for lowering LDL cholesterol in hyperlipidemia, results posted; completed statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• PCSK9 monoclonal antibody (PCSK9 inhibitor (monoclonal antibody))

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 2 | Status: COMPLETED | Results posted: 2015-10-01